Physician profile
Willard Howard
NPI 1487609541
$1,158.35
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.79 · 2020: $322 · 2021: $610 · 2022: $114 · 2023: $71.33 · 2024: $13.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $84.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $84.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $154.66 | 2020-2021 | |
| Amgen INC. | $152.65 | 2020-2021 | |
| Novo Nordisk INC | $144.93 | 2020-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $81.72 | 2020-2021 | |
| Genentech USA, INC. | $80.64 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.92 | 2021 | |
| Abbvie INC. | $68.94 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $59.82 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $54.44 | 2021 | |
| Pfizer INC. | $44.22 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $37.54 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.68 | 2020-2021 | |
| Astellas Pharma US INC | $29.68 | 2020-2021 | |
| Gilead Sciences, INC. | $23.97 | 2023 | Epclusa |
| Mylan Specialty L.P. | $18.27 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.80 | 2019 | |
| Dexcom, INC. | $16.54 | 2022 | |
| Lilly USA, LLC | $14.55 | 2022 | |
| Exact Sciences Corporation | $14.21 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $14.18 | 2021 | |
| Galderma Laboratories, L.P. | $13.36 | 2024 | |
| Glaxosmithkline, LLC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willard Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.